St. Jude Medical Price Target Increased to $51.00 by Analysts at Canaccord Genuity (STJ)
Equities research analysts at Canaccord Genuity hoisted their price target on shares of St. Jude Medical (NYSE:STJ) from $40.00 to $51.00 in a research note issued to investors on Thursday, Analyst Ratings.Net reports. The firm currently has a “sell” rating on the stock. Canaccord Genuity’s price target suggests a potential downside of 21.51% from the stock’s previous close.
Shares of St. Jude Medical (NYSE:STJ) traded down 0.92% during mid-day trading on Thursday, hitting $64.38. 320,862 shares of the company’s stock traded hands. St. Jude Medical has a 1-year low of $39.12 and a 1-year high of $68.39. The stock has a 50-day moving average of $62.26 and a 200-day moving average of $56.00. The company has a market cap of $18.787 billion and a price-to-earnings ratio of 26.53.
St. Jude Medical (NYSE:STJ) last released its earnings data on Wednesday, January 22nd. The company reported $0.99 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $0.02. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the prior year, the company posted $0.90 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts predict that St. Jude Medical will post $3.74 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of 0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.54%. The ex-dividend date of this dividend is Friday, December 27th.
Other equities research analysts have also recently issued reports about the stock. Analysts at Wedbush raised their price target on shares of St. Jude Medical from $62.00 to $73.00 in a research note to investors on Tuesday, January 14th. Separately, analysts at Barclays reiterated an “overweight” rating on shares of St. Jude Medical in a research note to investors on Thursday, January 9th. They now have a $72.00 price target on the stock, up previously from $65.00. Finally, analysts at BTIG Research initiated coverage on shares of St. Jude Medical in a research note to investors on Tuesday, January 7th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $56.94.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.